SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Provectus Pharmaceuticals Inc.
PVCT 0.06400.0%Nov 7 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Khris Smith who wrote (12692)2/10/2014 4:52:17 PM
From: Howard Williams1 Recommendation

Recommended By
Khris Smith

   of 13111
 
Yes Khris ... Moffitt's PV-10 immunology work moving up ........
***********************************************
Thanks to Dominic the Blogger in today's news ....

http://provectuspharmaceuticalsinc.blog … items.html

Moffitt @ ASCO 2014? (February 10, 2014)

Moffitt Cancer Center's Dr. Vernon Sondak will present PV-10 material on Friday, June 27th at the 4th European Post-Chicago Melanoma/Skin Cancer Meeting in Munich, Germany (see below). Note the company PV-10 will keep in the session: Bristol-Myers Squibb's Yervoy and Nivolumab, Merck's MK-3475, GlaxoSmithKline's MAGE-A3, and Amgen's T-Vec.



Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News